GlobalCast MD, along with Cincinnati Children's Hospital, sharing knowledge to improve child
health around the globe.
Hello pediatric surgery family.
I'm Cecilia Gigena, a research fellow from Cincinnati Children's Hospital Medical Center.
Our 11th annual update course in pediatric surgery was held this past August.
In this video, we are going to talk about management of recurrent pancreatitis.
And for that, we have Dr. Juan Gurria, a pediatric surgeon from Cincinnati Children's Hospital.
So first, we started with a case.
Seven-year-old with acute recurrent pancreatitis, abdominal pain, has a diagnosis of ARP, referred
to you with an ERCP showing a stricture in the head of the pancreas and a dilated duct
distal, we've seen this multiple times.
Has had seven ERCPs and a stent in the past.
So this is an ERCP.
So we have a clear stricture in the area of the head of the pancreas and a dilated duct
distal and you see clearly the branches.
So what is your plan?
MRCP to evaluate for chronic changes, repeat ERCP balloon dilation and stent placement,
MRCP and obtain genetics, or admin implant for FRIE procedure.
The FRIE procedure is a partial head pancreatectomy with duodenal preservation and a pancreatic
jejunostomy.
And it's interesting to see this very divided.
So the main is repeat ERCP.
So keep doing it.
We're seven ERCPs in.
The question is, when do you stop, right?
Every time you get an ERCP, you have a risk of getting post ERCP pancreatitis.
It's slow, right?
But still a risk and you lose eyelid cells with every attack.
So we're losing cells down the road.
And as he said, genetic is key.
So it is really important to get a genetic panel.
PRS1 is the most common one, which is a trypsinogen activator.
It activates trypsin inside the pancreas.
There's CTRC, CFTR, you know, CPA1.
There's a whole bunch of mutations that we now know.
Our gene panel in Cincinnati runs 10 different genetic markers.
So that's how we're changing the approach to pediatric pancreatitis, chronic pancreatitis
treatment because of the genetic factors.
Awesome.
So if a patient has more than one episode of acute pancreatitis or a first really bad
episode of it, we should perform an MRCP and a genetic panel to rule out genetic anomalies.
Now, you have that patient that has the mutation that they're there, trypsin activated.
How do you mediate that?
Is there medication or is there another path that you can do to?
Wonderful question.
No, no, there's no, unfortunately, we don't have that just yet.
That's why I still have a job.
But I hope some one day we have, you know, I would do a PUSTO on this kid.
What's the downside of that?
So excellent question.
If there's a generic mutation, say there's a PRS1 mutation, right?
For a PUSTO, you have to like get the top of the top half of the pancreas out to open
the duct, right?
You throw some eyelid cells to the trash.
This patient most likely is going to keep getting pancreatitis despite you draining
the duct.
The parenchyma is going to keep getting attacked by the mutation.
So you're temporizing the attack by draining the duct, but you're not fixing the problem.
Great.
So genetics are very important before any resection procedure to avoid losing pancreatic
cells in pathologies that will not benefit from a resection and drainage, but instead
from an eyelid cells transplant.
So I know the scenario pretty much points towards, okay, maybe recurrent or chronic
pancreatitis, but after how many do you feel like, okay, this is what we're dealing with?
Two, ERCPs, three, when do you start thinking considering that this might be a problem?
That's a great question.
We don't have a set number of ERCPs.
So there's no set limit on that, the sooner the referral, the better for an evaluation.
We don't offer to take out the pancreas unless you've maximized medical and endoscopic management.
If there's no other options and your endoscopic guy tells you, you know what, there's nothing
for me to balloon dilate, open drain or anything.
There's been a stent, even with the stent, the patient keeps getting pancreatitis.
There's no reason to keep going with ERCPs.
So do endoscopic treatment at first, but if it fails, transfer to a specialized center
that does TPIAT or total pancreatectomy with eyelid auto transplantation.
Now what about imaging for this patient?
So we use endoscopic ultrasound and ultrasound CT scan is imaging of choice once they come.
MRCP is the best non-invasive study for pancreas by far with different T2 sequences.
They're great and ERCP of course is more therapeutic than diagnostic.
Awesome.
Start with ultrasound, then CT and for better see the pancreatic anatomy, MRCP with T2 sequences.
Now what about fluid collections?
Once the wall is mature in four to six weeks, if there's symptoms, drain it.
If there's no symptoms, don't drain it.
If the patient is not having gastric alveolar obstruction or pain, there's no need to drain
this.
They will self-resolve and of course there's no need for antibiotics.
Awesome.
Time to summarize.
Recurrent pancreatitis is a rare pathology that can lead to chronic pancreatitis and it
is associated with genetic mutations.
If genetic mutations are confirmed, we should avoid partially resecting pancreatic tissue
as in a fry procedure to avoid losing pancreatic cells.
The treatment should start with endoscopic approach, keeping in mind that if it fails,
a TPIAT should be considered sooner rather than later.
For liquid collection, surgical treatment should be only done if the patient is symptomatic.
I hope you enjoyed the video and thank you for watching.
Don't forget to subscribe to the Stay Current MD YouTube channel.
Follow our social media channels and download the Stay Current MD app for tons of content
in pediatric surgery.
Global Cast MD along with Cincinnati Children's Hospital, sharing knowledge to improve child
health around the globe.